OrphanPacific Inc. Receives Manufacturing and Marketing Approval

OrphanPacific Inc. Receives Manufacturing and Marketing Approval of ORLADEYO Capsules 150mg for Suppression of HAE Attacks in Japan

January 22, 2021
OrphanPacific, Inc.
Torii Pharmaceutical Co., Ltd.

OrphanPacific, Inc.(OrphanPacific) and Torii Pharmaceutical Co., Ltd. (Torii) announced that OrphanPacific has today received manufacturing and marketing approval for ORLADEYO Capsules 150mg (generic name: berotralstat hydrochloride) (hereinafter “ORLADEYO”), a plasma kallikrein inhibitor indicated for the suppression of the onset of attacks in acute hereditary angioedema (HAE) in Japan.

Please visit OrphanPacific’s website for more details of the press release :
English Press Release: OrphanPacific Inc. Receives Manufacturing and Marketing Approval of ORLADEYO Capsules 150mg for Suppression of HAE Attacks in Japan

Inquiries about our services

Click below if you are interested in outsourcing your operations to us.

For access to this link, please complete this short form.
Name*
First Last
Company Name*
Email*
Country*
State*
How did you hear about us?*
Mailing
- Sign me up for future communications from CMIC Group
Comments
This field is for validation purposes and should be left unchanged.

EN | JP

Inquiries about our services

For access to this link, please complete this short form.